BioTime and subsidiary establish cell manufacturing facility in Israel

BioTime Inc. (NYSE:BTX) and its subsidiary Cell Cure Neurosciences said today that it is establishing an 800 square meter cell manufacturing facility at the Hadassah University Hospital in Jerusalem.

The manufacturing center will be staffed initially by 30 employees, according to the companies, and will be prepared to produce OpRegen for BioTime’s ongoing clinical trial program evaluating the cell therapy as a treatment for dry age-related macular degeneration.

Get the full story at our sister site, Drug Delivery Business News.

The post BioTime and subsidiary establish cell manufacturing facility in Israel appeared first on MassDevice.

from MassDevice http://ift.tt/2hOhQpR